You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Alliance Pharma plc (AIM: APH), the international healthcare group, will hold its Annual General Meeting ("AGM") at 10.00am this morning. At the meeting, the Group's Chairman, David Cook, will make the following statement:

“Firstly, on behalf of the Alliance Board, I would like to take this opportunity to thank Alliance’s employees around the world for their continued commitment and support through what for many, has been an extended period of remote working.

“As reported in March 2021, the year started well for the Group and we continue to see some strong performances from our key brands.

““Integration of the Biogix business and the Amberen brand into our US-based operations is progressing very well, with integration almost complete. Current trading and expectations for Amberen remain in line with our pre-acquisition forecasts.”

David Cook, Groups Chairman of Alliance will comment:

“We remain confident in our ability to weather any ongoing disruption to our business in those areas of the world which continue to be challenged by the global pandemic, and to deliver full year results in line with market expectations.

“Further commentary on our first half trading performance and full year outlook will be provided in mid July 2021 in our half year trading update.”

AGM 2021: Access details for shareholders

Alliance’s AGM is being held as a hybrid meeting at Group's head office, Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB, alongside a live and interactive broadcast to shareholders.

As detailed in the Notice of AGM, a copy of which can be viewed at https://www.alliancepharmaceuticals.com/media/j2phk41u/alliance-pharma-agm-notice-final.pdf,

We are strongly urging shareholders not to attend the AGM in person this year but instead take part in the AGM remotely, using the access details below:

Meeting website: https://web.lumiagm.com

Meeting ID: 145-852-162

Shareholders will also require their unique 11-digit Investor Code (IVC) and PIN to access the meeting. Full details on how to attend the 2021 AGM and vote can be found in the AGM Notice.

For further information:

Alliance Pharma plc
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
+ 44 (0)1249 466966

Buchanan
Mark Court / Sophie Wills / Hannah Ratcliff
alliancepharma@buchanan.uk.com
+ 44 (0)20 7466 5000

Numis Securities Limited
Nominated Adviser: Freddie Barnfield / Huw Jeremy
Corporate Broking: James Black
+ 44 (0)20 7260 1000

Investec Bank plc
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
+ 44 (0) 20 7597 5970

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com